Literature DB >> 22721663

Pathology of drug-eluting versus bare-metal stents in saphenous vein bypass graft lesions.

Saami K Yazdani1, Andrew Farb, Masataka Nakano, Marc Vorpahl, Elena Ladich, Aloke V Finn, Frank D Kolodgie, Renu Virmani.   

Abstract

OBJECTIVES: The purpose of this study was to assess the pathological responses of atherosclerotic saphenous vein bypass grafts (SVBGs) to drug-eluting stents (DES) versus bare-metal stents (BMS).
BACKGROUND: Repeat bypass surgery is typically associated with a high rate of morbidity and mortality. Percutaneous coronary interventions have emerged as the preferred treatment; however, only limited data are available on SVBGs pathological responses to DES and BMS.
METHODS: Formalin-fixed SVBG of >2 years duration (n = 31) were collected to histologically characterize advanced atherosclerotic lesions in native SVBG. In a separate group, SVBGs treated with DES (n = 9) and BMS (n = 9) for >30 days duration were assessed for morphological and morphometric changes.
RESULTS: Necrotic core lesions were identified in 25% of SVBG sections, and plaque rupture with luminal thrombosis was observed in 6.3% of histological sections (32% [10 of 31] vein grafts examined). Morphometry of DES demonstrated reduction in neointimal thickening versus BMS (0.13 mm [interquartile range: 0.06 to 0.16 mm] vs. 0.30 mm [interquartile range: 0.20 to 0.48 mm], p = 0.004). DES lesions also showed greater delayed healing characterized by increased peristrut fibrin deposition, higher percentage of uncovered struts, and less endothelialization compared with BMS. Stent fractures (DES 56% vs. BMS 11%, p = 0.045) and late stent thrombosis (DES 44% vs. BMS 0%, p = 0.023) were more common in DES versus BMS.
CONCLUSIONS: Advanced SVBG atherosclerotic lesions are characterized by large hemorrhagic necrotic cores. Stenting of such lesions is associated with delayed vascular healing and late thrombosis particularly following DES implantation, which may help explain the higher rates of cardiovascular events observed in SVBG stenting as compared with native coronary arteries.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22721663      PMCID: PMC3407956          DOI: 10.1016/j.jcin.2011.12.017

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  36 in total

1.  Are we making progress with percutaneous saphenous vein graft treatment? A comparison of 1990 to 1994 and 1995 to 1998 results.

Authors:  M K Hong; R Mehran; G Dangas; G S Mintz; A Lansky; K M Kent; A D Pichard; L F Satler; G W Stone; M B Leon
Journal:  J Am Coll Cardiol       Date:  2001-07       Impact factor: 24.094

2.  The effects of extremely low shear stress on cellular proliferation and neointimal thickening in the failing bypass graft.

Authors:  S L Meyerson; C L Skelly; M A Curi; U M Shakur; J E Vosicky; S Glagov; L B Schwartz; T Christen; G Gabbiani
Journal:  J Vasc Surg       Date:  2001-07       Impact factor: 4.268

Review 3.  Saphenous vein graft disease.

Authors:  S Peykar; D J Angiolillo; T A Bass; M A Costa
Journal:  Minerva Cardioangiol       Date:  2004-10       Impact factor: 1.347

4.  Aortocoronary saphenous vein bypass grafts. Long-term patency, morphology and blood flow in patients with patent grafts early after surgery.

Authors:  R I Hamby; A Aintablian; M Handler; C Voleti; D Weisz; J W Garvey; G Wisoff
Journal:  Circulation       Date:  1979-10       Impact factor: 29.690

Review 5.  Aortocoronary saphenous vein bypass grafts.

Authors:  R Virmani; J B Atkinson; M B Forman
Journal:  Cardiovasc Clin       Date:  1988

6.  Incidence, risk, and outcome of reintervention after aortocoronary bypass surgery.

Authors:  K Laird-Meeter; R van Domburg; M J van den Brand; J Lubsen; E Bos; P G Hugenholtz
Journal:  Br Heart J       Date:  1987-05

7.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

8.  Histology after stenting of human saphenous vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent implantation.

Authors:  H M van Beusekom; W J van der Giessen; R van Suylen; E Bos; F T Bosman; P W Serruys
Journal:  J Am Coll Cardiol       Date:  1993-01       Impact factor: 24.094

9.  Morphological predictors of restenosis after coronary stenting in humans.

Authors:  Andrew Farb; Deena K Weber; Frank D Kolodgie; Allen P Burke; Renu Virmani
Journal:  Circulation       Date:  2002-06-25       Impact factor: 29.690

10.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

Authors:  Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

View more
  9 in total

1.  Why is the mammary artery so special and what protects it from atherosclerosis?

Authors:  Fumiyuki Otsuka; Kazuyuki Yahagi; Kenichi Sakakura; Renu Virmani
Journal:  Ann Cardiothorac Surg       Date:  2013-07

Review 2.  Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization.

Authors:  Frans J Beerkens; Bimmer E Claessen; Marielle Mahan; Mario F L Gaudino; Derrick Y Tam; José P S Henriques; Roxana Mehran; George D Dangas
Journal:  Nat Rev Cardiol       Date:  2021-10-05       Impact factor: 32.419

3.  Inhibiting intimal hyperplasia in prosthetic vascular grafts via immobilized all-trans retinoic acid.

Authors:  Elaine K Gregory; Antonio Webb; Janet M Vercammen; Megan E Kelly; Banu Akar; Robert van Lith; Edward M Bahnson; Wulin Jiang; Guillermo A Ameer; Melina R Kibbe
Journal:  J Control Release       Date:  2018-01-31       Impact factor: 9.776

Review 4.  Vein graft failure: from pathophysiology to clinical outcomes.

Authors:  Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2016-05-19       Impact factor: 32.419

Review 5.  Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis.

Authors:  Kazuyuki Yahagi; Frank D Kolodgie; Fumiyuki Otsuka; Aloke V Finn; Harry R Davis; Michael Joner; Renu Virmani
Journal:  Nat Rev Cardiol       Date:  2015-10-27       Impact factor: 32.419

Review 6.  Saphenous vein grafts in contemporary coronary artery bypass graft surgery.

Authors:  Etem Caliskan; Domingos Ramos de Souza; Andreas Böning; Oliver J Liakopoulos; Yeong-Hoon Choi; John Pepper; C Michael Gibson; Louis P Perrault; Randall K Wolf; Ki-Bong Kim; Maximilian Y Emmert
Journal:  Nat Rev Cardiol       Date:  2019-08-27       Impact factor: 32.419

7.  A Rabbit Model for Testing Helper-Dependent Adenovirus-Mediated Gene Therapy for Vein Graft Atherosclerosis.

Authors:  Lianxiang Bi; Bradley K Wacker; Emma Bueren; Ervin Ham; Nagadhara Dronadula; David A Dichek
Journal:  Mol Ther Methods Clin Dev       Date:  2017-09-28       Impact factor: 6.698

Review 8.  Inflammation in Vein Graft Disease.

Authors:  Margreet R de Vries; Paul H A Quax
Journal:  Front Cardiovasc Med       Date:  2018-01-24

Review 9.  The Role of Immunomodulation in Vein Graft Remodeling and Failure.

Authors:  Fabiana Baganha; Alwin de Jong; J Wouter Jukema; Paul H A Quax; Margreet R de Vries
Journal:  J Cardiovasc Transl Res       Date:  2020-06-16       Impact factor: 4.132

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.